For the six months ended June 30, 2025, general and administrative expenses were $1.9 million, compared to $1.5 million for the six months ended June 30, 2024. The increase was mainly attributable to higher legal costs and share-based compensation expenses. Research and development expenses were $0.3 million for the six months ended June 30, 2025, compared to $11.4 million for the six months ended June 30, 2024. The decrease was primarily due to the completion of the Phase 3 clinical trial evaluating PRF-110 in 2024. Financial income, net, was $52,000 for the six months ended June 30, 2025, compared to $92,000 for the six months ended June 30, 2024. The decrease was primarily due to lower cash balances in 2025. Net loss for the six months ended June 30, 2025, was $2.3 million, compared to $12.8 million for the six months ended June 30, 2024. As of June 30, 2025, cash and cash equivalents (including restricted cash) were $3.5 million, and working capital was $1.5 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PainReform Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538443-en) on October 01, 2025, and is solely responsible for the information contained therein.
Comments